Display options
Cite
Roberts R. Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease. Curr Atheroscler Rep. 2016;18(12):78doi: 10.1007/s11883-016-0628-8.
Roberts, R. (2016). Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease. Current atherosclerosis reports, 18(12), 78. https://doi.org/10.1007/s11883-016-0628-8
Roberts, Robert. "Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease." Current atherosclerosis reports vol. 18,12 (2016): 78. doi: https://doi.org/10.1007/s11883-016-0628-8
Roberts R. Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease. Curr Atheroscler Rep. 2016 Dec;18(12):78. doi: 10.1007/s11883-016-0628-8. PMID: 27815829.
Copy Download .nbib Format: NLM
Share it on

Curr Atheroscler Rep. 2016 Dec;18(12):78. doi: 10.1007/s11883-016-0628-8.

Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease.

Current atherosclerosis reports

Robert Roberts

Affiliations

  1. University of Arizona College of Medicine-Phoenix, 550 East Van Buren, Phoenix, AZ, 85004, USA. [email protected].

PMID: 27815829 DOI: 10.1007/s11883-016-0628-8

Abstract

PURPOSE OF REVIEW: The purpose of this study is to review genetic risk variants for coronary artery disease (CAD) and how they will change the management and prevention of CAD currently and in the future.

RECENT FINDINGS: Through the efforts of international consortia, 58 genetic risk variants for CAD of genome-wide significance have been replicated in appropriate independent populations. Only one third of these variants mediate their risk through known conventional risk factors for CAD. Thus, unknown mechanisms contribute to CAD. Secondly, the genetic risk is proportional to the total number of risk variants rather than the intensity of any risk factor. Thirdly, the availability of the genetic risk variants enables one to perform Mendelian randomization (MR) studies since they are randomized at conception, not confounded, fixed for life, and can be used to determine if a risk factor is causative or just a marker. MR can also be used to determine the safety and efficacy of a gene product targeted for drug therapy. Genetic risk variants have been shown to successfully risk stratify for CAD in both primary and secondary preventions. Contrary to dogma, MR documents that plasma HDL-C is not protective of CAD. The use of genetic risk score (GRS) for CAD is shown to be more effective in risk stratifying for CAD than the Framingham risk score and independent of the conventional risk factors including family history. Furthermore, the GRS predicts the response to statin therapy in primary and secondary preventions. The use of GRS could represent a paradigm shift in the prevention of CAD.

Keywords: Coronary artery disease; Genetic risk score for CAD; Genetic risk stratifications for CAD; Genetics; Mendelian randomization

References

  1. Circ Res. 2014 Jun 6;114(12):1890-903 - PubMed
  2. Int J Epidemiol. 2015 Apr;44(2):682-8 - PubMed
  3. Eur Heart J. 2014 Aug 1;35(29):1917-24 - PubMed
  4. N Engl J Med. 1994 Apr 14;330(15):1041-6 - PubMed
  5. N Engl J Med. 2011 Dec 15;365(24):2255-67 - PubMed
  6. N Engl J Med. 2015 Jan 15;372(3):295-6 - PubMed
  7. Curr Atheroscler Rep. 2008 Jun;10(3):186-93 - PubMed
  8. Nat Genet. 2003 Jun;34(2):154-6 - PubMed
  9. Nat Genet. 2011 Mar 06;43(4):333-8 - PubMed
  10. Lancet. 2015 Jun 6;385(9984):2264-2271 - PubMed
  11. JAMA. 2014 Sep 10;312(10):1006-15 - PubMed
  12. Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2281-9 - PubMed
  13. BMJ. 2003 Jun 28;326(7404):1419 - PubMed
  14. Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73 - PubMed
  15. Science. 2007 Jun 8;316(5830):1491-3 - PubMed
  16. Am J Hum Genet. 2012 Mar 9;90(3):410-25 - PubMed
  17. Eur Heart J. 2016 Feb 7;37(6):561-7 - PubMed
  18. JAMA. 2014 Jan 15;311(3):252-62 - PubMed
  19. J Am Coll Cardiol. 2012 Dec 25;60(25):2631-9 - PubMed
  20. Nature. 2010 Aug 5;466(7307):707-13 - PubMed
  21. Nat Genet. 2015 Oct;47(10 ):1121-1130 - PubMed
  22. Atherosclerosis. 2015 Apr;239(2):451-8 - PubMed
  23. J Intern Med. 2002 Sep;252(3):247-54 - PubMed
  24. Nat Genet. 2009 Mar;41(3):334-41 - PubMed
  25. Twin Res. 2001 Aug;4(4):266-74 - PubMed
  26. Nat Genet. 2013 Jan;45(1):25-33 - PubMed
  27. N Engl J Med. 2006 Mar 23;354(12 ):1264-72 - PubMed
  28. Nat Genet. 2009 Mar;41(3):280-2 - PubMed
  29. BMJ. 2014 Jul 18;349:g4379 - PubMed
  30. Circulation. 2010 Jun 1;121(21):2284-93 - PubMed
  31. Lancet. 2012 Aug 11;380(9841):572-80 - PubMed
  32. Eur J Intern Med. 2012 Dec;23(8):745-54 - PubMed
  33. Science. 2007 Jun 8;316(5830):1488-91 - PubMed
  34. Curr Opin Cardiol. 2013 Jul;28(4):389-98 - PubMed
  35. Can J Cardiol. 2013 Aug;29(8):899-901 - PubMed
  36. Lancet. 2004 Sep 11-17;364(9438):937-52 - PubMed
  37. N Engl J Med. 1976 Jun 17;294(25):1386-90 - PubMed
  38. N Engl J Med. 2007 Aug 2;357(5):443-53 - PubMed
  39. JAMA. 2010 Feb 17;303(7):648-56 - PubMed
  40. N Engl J Med. 2015 May 14;372(20):1972 - PubMed
  41. Int J Cardiol. 2013 Aug 10;167(3):646-55 - PubMed
  42. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33 - PubMed
  43. Front Genet. 2014 Aug 01;5:254 - PubMed
  44. J Am Coll Cardiol. 2015 Apr 21;65(15):1567-82 - PubMed
  45. J Lipid Res. 2011 Jan;52(1):78-86 - PubMed
  46. J Am Coll Cardiol. 2013 Nov 19;62(21):1966-1976 - PubMed
  47. Nat Genet. 2016 Oct;48(10 ):1171-1184 - PubMed
  48. J Mol Med (Berl). 2008 Nov;86(11):1233-41 - PubMed
  49. Nat Genet. 2013 Nov;45(11):1274-1283 - PubMed
  50. Nat Genet. 2011 Mar 06;43(4):339-44 - PubMed
  51. Circ Cardiovasc Genet. 2015 Apr;8(2):356-62 - PubMed
  52. Nature. 2011 Sep 11;478(7367):103-9 - PubMed
  53. Nat Genet. 2009 Mar;41(3):342-7 - PubMed
  54. Circulation. 2010 Nov 30;122(22):2323-34 - PubMed
  55. Nat Genet. 2012 Sep;44(9):981-90 - PubMed
  56. N Engl J Med. 2014 May 1;370(18):1702-11 - PubMed
  57. Nature. 2003 Dec 18;426(6968):789-96 - PubMed
  58. Circ Cardiovasc Genet. 2014 Apr;7(2):144-50 - PubMed

MeSH terms

Publication Types